Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
huSPAST-HA-R499H Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

huSPAST-HA-R499H Mouse

Product Name
huSPAST-HA-R499H Mouse
Product ID
C002144
Strain Name
C57BL/6Cya-Spasttm2(HA tag-hSPAST*R499H)/Cya
Background
C57BL/6Cya
Status
Live Mouse
When using this mouse strain in a publication, please cite “huSPAST-HA-R499H Mouse (Catalog C002144) were purchased from Cyagen.”
HUGO-GT Humanized ModelsNeurodegenerative Diseases
mAb
Gene Editing Therapy
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
HUGO-GT Humanized ModelsNeurodegenerative Diseases
mAb
Gene Editing Therapy

Basic Information

Related Resource
Basic Information
Gene Name
SPAST
Gene Alias
FSP2, SPG4, ADPSP
NCBI ID
6683 (Human)
Chromosome
Chr 2 (Human)
MGI ID
MGI:1858896
Datasheet
Click here to download >>

Strain Description

Hereditary spastic paraplegia (HSP) is a hereditary neurodegenerative disease characterized pathologically by retrograde axonal degeneration of the corticospinal tract and the posterior columns of the spinal cord. Its clinical manifestations include progressive spastic weakness of both lower limbs, scissor gait, hyperreflexia, and positive pathological signs. The prevalence of autosomal dominant HSP is approximately 1–5 per 100,000, and it usually begins in young adulthood. SPG4, caused by mutations in the SPAST gene, is the most common autosomal dominant HSP subtype, accounting for about 40% of all autosomal dominant HSP families [1-3], and it is also the most common subtype in Chinese autosomal dominant HSP cohorts [4]. Spastin, encoded by SPAST, is a member of the AAA+ ATPase family. By severing microtubules, it regulates microtubule length, dynamics, and axonal transport, and is essential for maintaining cytoskeletal homeostasis in long axons [5]. SPAST mutations are predominantly missense, nonsense, and splice-site variants; whole-gene deletions can also cause the disease. Loss of function (haploinsufficiency) is the primary pathogenic mechanism. Decreased microtubule-severing activity leads to impaired axonal transport and distal axonal degeneration, ultimately resulting in progressive spastic paraplegia [3,6]. There is currently no disease-modifying therapy for SPG4; clinical management is mainly symptomatic treatment of spasticity.
The p.Arg499His (R499H) variant is a missense mutation in the SPAST gene caused by a nucleotide substitution at c.1496G>A (NM_014946.4), resulting in the replacement of arginine (Arg) with histidine (His) at amino acid position 499 of the Spastin protein. This variant is located within the AAA domain of Spastin and may affect its normal function. It has been reported in multiple clinical studies to be associated with hereditary spastic paraplegia type 4 (SPG4). Affected individuals may exhibit infantile-onset symptoms, including lower limb spasticity and delayed motor development. Some cases may also present with dystonia, dysarthria, and cognitive impairment [7-8].
huSPAST-HA-R499H mice were generated using gene-editing technology by replacing the sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the human TAA stop codon, and the p.R499H (CGT to CAT) mutation was introduced into exon 13 of the human SPAST gene. This model can be used to investigate the pathogenesis of hereditary spastic paraplegia type 4 (SPG4) associated with the SPAST R499H mutation, as well as to support the development and efficacy evaluation of targeted therapeutics.
Reference
Salinas S, et al. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127-1138.
Ruano L, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183.
Fonknechten N, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637-644.
Zhao M, et al. Genetic and Clinical Profile of Chinese Patients with Autosomal Dominant Spastic Paraplegia. Mol Diagn Ther. 2019;23(6):781-789.
Roll-Mecak A, et al. Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature. 2008;451(7176):363-367.
Patrono C, et al. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol. 2002;249(2):200-205.
Nan H, et al. A p.Arg499His mutation in SPAST is associated with infantile-onset complicated spastic paraplegia: a case report and review of the literature. BMC Neurol. 2021 Nov 9;21(1):439.
Mo A, et al. Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST. Mov Disord. 2022 Dec;37(12):2440-2446.

Strain Strategy

The sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the TAA stop codon of the human SPAST gene, and the p.R499H (CGT to CAT) mutation was introduced into human SPAST exon 13.
Figure 1. Gene editing strategy of huSPAST-HA-R499H mice.
Figure 1. Gene editing strategy of huSPAST-HA-R499H mice.

Application Area

Research on the pathogenesis of hereditary spastic paraplegia type 4 (SPG4);
Screening, development, and preclinical in vivo evaluation of SPAST-targeted therapies.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research